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Background: The effects of cinacalcet in persistent and/or hypercalcaemia-associated sec-
ondary hyperparathyroidism (SHPT) have been described in patients on dialysis.
Objectives: To evaluate the efﬁcacy and safety of cinacalcet in SHPT not on dialysis and its
effects on bone turnover markers.
Methods: Non-randomised, longitudinal, observational, analytical study of patients with
chronic kidney disease (CKD) and SHPT (PTH >80 pg/mL) as well as normo- or hypercalcaemia
(≥8.5 mg/dL), treated with cinacalcet.
Results: Mean cinacalcet dose was 30 mg/day in 66.7%. We  studied 15 patients (10 women),
aged 66.0 ± 17.93 years. The aetiology was unknown in 20% of cases. Sociodemographic
variables and renal function parameters were recorded. We  compared values at baseline as
well  as after 6 and 12 months. Calcium (10.3 ± 0.55 vs. 9.4 ± 1.04) and iPTH (392.4 ± 317.65 vs.
141.8  ± 59.26) levels decreased. Increased levels of phosphorus (3.7 ± 1.06 vs. 3.9 ± 0.85) and
-CTX  (884.2 ± 797.22 vs. 1053.6 ± 999.00) were detected, although there were no signiﬁcant
changes in GFR, urinary calcium or other bone markers. Two patients withdrew from the
study (gastrointestinal intolerance and parathyroidectomy, respectively).
Conclusions: Cinacalcet at low doses is effective in the management of SHPT in CKD patients
who  are not on dialysis. Its use reduces iPTH and calcaemia, without causing serious side
effects or signiﬁcant changes in renal function.© 2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
 Please cite this article as: Orellana JM, Esteban RJ, Castilla YA, Fernández-Castillo R, Nozal-Fernández G, Esteban MA,  et al. Uso de
inacalcet para el control del hiperparatiroidismo en pacientes con diferentes grados de insuﬁciencia renal. Nefrología. 2016;36:121–125.
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Uso  de  cinacalcet  para  el  control  del  hiperparatiroidismo  en  pacientes  con
diferentes  grados  de  insuﬁciencia  renal
Palabras clave:
Cinacalcet
Enfermedad renal crónica
Hiperparatiroidismo secundario
Hormona paratiroidea
Calcio
Fósforo
Marcadores de recambio óseo
r  e  s  u  m  e  n
Antecedentes: Los efectos de cinacalcet en el hiperparatiroidismo secundario (HPTS), persis-
tente o asociado a hipercalcemia han sido descritos en pacientes en diálisis.
Objetivos: Analizar la eﬁcacia y seguridad de cinacalcet en HPTS no sometido a diálisis y sus
efectos sobre marcadores de recambio óseo.
Métodos: Estudio analítico observacional, no aleatorizado, longitudinal, de pacientes con
enfermedad renal crónica (ERC) e HPTS (PTH > 80 pg/mL); con normohipercalcemia
(≥8,5 mg/dL), tratados con cinacalcet.
Resultados: La dosis media de cinacalcet fue de 30 mg/día en un 66,7%. Estudiamos 15
pacientes (10 mujeres), con edad de 66,0 ± 17,93 an˜os. Etiología desconocida en 20% de los
casos.  Registramos variables sociodemográﬁcas y parámetros de función renal. Compara-
mos  valores basales, tras 6 y 12 meses. Descendieron los niveles de iPTH (392,4 ± 317,65 vs.
141,8 ± 59,26) y calcio (10,3 ± 0,55 vs. 9,4 ± 1,04). Aumentaron los valores de fósforo (3,7 ± 1,06
vs.  3,9 ± 0,85) y ß-CTX (884,2 ± 797,22 vs. 1.053,6 ± 999,00), sin variaciones signiﬁcativas del
FG, calciuria y demás marcadores óseos. Registrados 2 abandonos (intolerancia digestiva y
paratiroidectomía, respectivamente).
Conclusiones: Cinacalcet a dosis bajas es eﬁcaz en el manejo del HPTS del paciente con ERC no
tratado mediante diálisis, al disminuir la iPTH y la calcemia, sin ocasionar efectos adversos
graves ni variación signiﬁcativa de la función renal.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U.
Este es un artículo Open Access bajo la licencia CC BY-NC-NDIntroduction
Cinacalcet (Mimpara®) is currently the only calcimimetic with
an approved indication for the treatment of secondary hyper-
parathyroidism (SHPT) in patients with chronic kidney disease
(CKD) on dialysis,1–3 as well as in primary hyperparathy-
roidism (PHPT) caused by parathyroid adenoma or carcinoma
in patients who have not undergone a parathyroidectomy, or
with persistence of the disease following parathyroidectomy.2
Also, it has been used successfully in residual SHPT from a
kidney transplant, although it does not a formal indication4
in these patients.
The calcimimetics acts as a positive allosteric modulator
of the calcium-sensor receptors expressed in multiple tis-
sues such as the parathyroid glands, kidneys, bone (especially
in osteoclasts) and blood vessels.5 Its activation increases
signal transduction, presumably inducing intracellular con-
formational changes and reducing the threshold for calcium
sensitivity. At the glandular level, this translates to lower pro-
duction and secretion of parathyroid hormone (PTH), which
is essential in the management of resistant SHPT and SHPT
associated with hypercalcaemia in patients in dialysis, in
whom it has also shown modiﬁcation of bone turnover
markers.6,7
Less known are the effects of calcimimetics on patients
with abnormal renal function not on dialysis, in whom
mineral and bone disorder (MBD) associated with CKD is
present.5–7 The latter does not strictly include only abnor-
malities in calcium, phosphorus, PTH and vitamin D; it also
comprises abnormalities in bone remodelling, volume and
resistance; as well as vascular and soft-tissue calciﬁcations.7,8(http://creativecommons.org/licenses/by-nc-nd/4.0/).
In patients with CKD, the determination of collagen degrada-
tion products and classic bone turnover markers have greater
utility than bone densitometry to predict the risk of fractures.
Hence the importance of studying these parameters.7
This work aims to determine the efﬁcacy and safety of
cinacalcet in the treatment of SHPT in patients with CKD
not treated with renal replacement therapy, in whom,  owing
to their serum calcium levels, the use of vitamin D and its
derivatives is not safe, and in patients with severe hyper-
parathyroidism with a contraindication for surgery. It also
aims to describe its effects on bone remodelling markers.
Patients  and  methods
We conducted an observational, longitudinal study in a
cohort of patients followed in our outpatient clinics. Patients
enrolled had a diagnosis of SHPT (iPTH level > 80 pg/ml),
whether with hypercalcaemia (which limited the use of both
calcium-chelating agents and vitamin D and its analogues)
or with normocalcaemia (corrected calcium ≥8.5 mg/dl) resis-
tant to these treatments. Patients were on stages 3–5 CKD
(estimated glomerular ﬁltration rate [eGFR] between 60 and
<15 ml/min/1.73 m2).
The sociodemographic variables of the sample were
recorded.
In each patient the use of cinacalcet for compassionate use
was requested and authorised.
The patients started treatment with cinacalcet at a dose of
30 mg in a single dose taken in the morning, and the dose
was adjusted according to the evolution of the measured
parameters.
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The eGFR was calculated using the MDRD-4 formula, and
PTH, calcium, phosphorus, osteocalcin (OC), total alkaline
hosphatase (AP), beta-crosslaps (-CTX) and P1NP levels
ere determined using our laboratory’s standard techniques.9
hese variables were recorded at baseline, 6 months and 12
onths from the start date of treatment with cinacalcet. We
ecorded adverse reactions and suspensions of this treatment,
s well as associated medication based on phosphorus-
helating agents (both calcium and non-calcium), vitamin D
nalogues and biphosphonates.
The discrete variables were summarised using frequencies
nd percentages, and continuous variables were summarised
sing means ± standard deviations (SDs), medians and per-
entiles (P25 and P75). The analysis was performed with the
reatest number of subjects with observed and recorded data
or each variable, since lost values were not replaced; in all
ases it was always n ≥ 9. We  used Friedman’s 2-way analysis
o study the change in the variables at baseline, 6 months and
2 months, and the Wilcoxon signed-rank test for the change
fter a year. The statistical analyses were performed using
he IBM® SPSS® Statistics v. 19 software program. The level
f signiﬁcance was set at p < 0.05.
esults
 total of 15 patients were enrolled; 10 were women, and the
ean age was 66.0 ± 17.9 years. They were distributed as CKD
 (8 patients), CKD4 (3 patients) and CKD 5 (4 patients). The
ause of CKD was vascular (7 patients), glomerular (3 patients),
nterstitial (one patient), diabetic (one patient) or of unknown
rigin (4 patients).
Before starting treatment with cinacalcet, 50.0% of patients
ere taking paricalcitol, 13.3% were taking non-calcium
hosphorus-chelating agents and 26.6% were taking biphos-
honates; these agents were continued. The starting dose of
inacalcet in most patients was 30 mg/day, and after a year the
ean dose of cinacalcet was 36.2 ± 14.1 mg/24 h.
Table 1 shows the evolution of eGFR and bone and mineral
etabolism parameters following the treatment with cinacal-
et, as well as the results of the comparisons performed.
Before therapy the mean iPTH was 392.4 ± 317.6, and
ean blood calcium concentration was 10.3 ± 0.5 mg/dl. After
2 months of treatment he PTH levels decrease by 64%
Mean12 months = 141.8) that was statistically signiﬁcant as
ompared with baseline (Friedman, 2(2) = 8.222; p = 0.016;
ilcoxon, Z = −2.599; p = 0.009). The values of serum calcium
ecreased by 9.0% (Mean12 months = 9.4 mg/dl) this fall was sig-
iﬁcant as compared with baseline, (Friedman, 2(2) = 7.800;
 = 0.02; Wilcoxon, Z = −2.832; p = 0.005) (Table 1 and Fig. 1).
We  also observed a 5.0% increase in the mean serum
hosphorus concentration after the one year of treatment
Mean12 months = 3.9 mg/dl) as compared with the baseline
alues (MeanBaseline = 3.7 mg/dl); this was not statistically
igniﬁcant according to Friedman, 2(2) = 5.250; p = 0.072,
lthough it was signiﬁcant according to Wilcoxon, Z = −2.599; = 0.011. We  also found a 19.0% increase in the levels of
he bone resorption marker -CTX after 12 months (Mean12
onths = 1053 pg/ml) compared with the baseline CTX val-
es (MeanBaseline = 885 pg/ml); this change was signiﬁcant
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Fig. 1 – Percent change in eGFR and in bone and mineral
metabolism after treatment with cinacalcet between values
at baseline and at 12 months. *Represents statistical
signiﬁcance.
according to the Wilcoxon rank test (Z = −2.045; p = 0.041); but
did not reach statistical signiﬁcance according to Friedman,
2(2) = 1.000; p = 0.607. There were no signiﬁcant differences in
the mean values for calciuria, eGFR, OC, P1NP or AP.
In two patients (13.3%) cinacalcet was discontinued: one
due to gastrointestinal intolerance and the other patient
because parathyroidectomy.
Discussion
Our pilot study has demonstrated that cinacalcet is effective in
the management of SHPT associated with CKD in patients not
yet in dialysis PTH levels decreased togheter with a reduction
in serum calcium levels without detection of serious adverse
events.
SHPT and MBD  are present in patients with CKD.1,3,5–7 Both
clinical conditions involve a substantial healthcare burden
owing to their broad association with increase in cardio-
vascular risk, mortality and onset of fractures.3,5,8 Some
studies even highlighted the differential involvement of each
MBD  factor in mortality (calcium/mortality > phosphorus/
mortality > PTH/mortality ratio).3,8 In patients with CKD man-
agement of SHPT and MBD  is made by controlling the
triggering factors: through dietary restriction of phospho-
rus, the use of both calcium and non-calcium chelating
agents, and correction of deﬁciencies such as vitamin D (or
its analogues).3,6,10 On occasion, the above-mentioned meas-
ures are not effectve, and may be even have adverse effects as
they increase the risk of vascular or soft-tissue calciﬁcations
in patients with high baseline blood calcium levels.5,11
Calcimimetics offer a therapeutic advantage as they act on
the main physiopathological factors of both entities, which
are already broadly related. Firstly, they reduce serum lev-
els of PTH by decreasing its gene expression and secondly,
they stimulate the synthesis of vitamin D receptors in the
parathyroid gland, thereby increasing sensitivity to vitamini
D with the subsequent PTH suppression.2,5,6,12,13 Some stud-
ies demonstrate tha cacimimetics stimulate calcitonin, which
would cause a reduction in serum calcium levels. Regarding;3 6(2):121–125
the serum phosphorus concentration, it is known that with
GFR < 60 ml/min/1.73 m2, there is an increase in the serum
concentration of the phosphaturic hormone FGF-23, that also
inhibits calcitriol synthesis.2,3 The increase in FGF23 is con-
sidered a physiological adaptation aimed to maintain better
controlled phosphorus levels until advanced stages of CKD.3
There is limited informatio on the effect of cinacalcet in
CKD outside of dialysis. To the best of our knowledge thera
are two studies,4,5 neither of which investigates the effects
of the drug in early stages of CKD or the effects on cal-
cimimetics on bone remodelling. Therefore, our ﬁndings will
be novel. We  found that, after one year of cinacalcet in patients
with stage 3–5 CKD (KDOQI), the serum iPTH levels signiﬁ-
cantly decreased, by around 65%, and serum calcium levels
was reduced by almost 10% from baseline values. The above
results match the observations in dialysis patients.1,5,12 There
is considerable correlation between the reduction of PTH in
dialysis and in CKD patients.1,3,11 However, there were dis-
cordant results with respect to serum levels of phosphorus
and -CTX which in dialyisi patients are normally reduced
acter calcimimetics treatment.8,10–13 Therefore, the outcomes
did not correspond to the respective 5% and 19% increases
that our cohort presented. This latter results are probably
explained by the reducton in PTH that deprive patients with
signiﬁcant GFR from the phosphaturic effects of PTH, in addi-
tion to the implication of cinacalcet in the reduction of FGF-23
levels.12
Bone remodelling markers are a dynamic reﬂection of the
synthesis/degradation activity of the entire skeleton; this is
different from densitometry/radiography, which focus on a
static part of bone activity. Under normal conditions, the bone
remodelling cycle last 3–6 months. Degradation of type I col-
lagen results in blood and urine detection of both aminoxy
terminal and carboxy terminal portions.14 There are more spe-
ciﬁc markers of bone formation, some are related to osteoblast
activity (OC, P1NP and AP) and others are more  related to
bone resorption and osteoclast activity (ICTP, CTX and NTX).14
Their usefulness is based on the determination of the rate
of bone turnover and risk of fractures and their function as
a prognostic factor for response to treatment of metabolic
bone diseases.7,14 However, to assess bone health, biopsy
and tetracycline labelling remain the gold standard.7,14 -CTX
monitoring is useful in verifying response to antiresorptive
therapy; the higher the initial values of this marker, the greater
the response.1,6,7,12 The evolution of -CTX levels did not
correspond to what had been observed in previous works con-
ducted in hemodialysis patients on cinacalcet1; however, we
do not have studies in patients with CKD not in dialysis. It
should be mentioned that around 27% of the patients included
in our study were treated with antiresorptive agents, as they
had GFR greater than 30 ml/min. We are not certain whether
there are implications associated with the use of cinacalcet
and our ﬁndings. We  believe that this subject should be further
explored.
We did not observe any trends towards improvement of
GFR, or changes in calciuria therefore the reduction in serum
calcium concentration should not be related to urine losses.
Our conclusions may be limited by the small number of
patients and the method of data collection which can lead to
selection or information bias.
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onclusion
inacalcet effectively decreases iPTH and calcium levels in
atients with CKD not in renal replacement therapy. Safety
s similar to the observed in dialysis patients; no adverse
ffects occurred during the observation period. No signiﬁcant
ariation in renal function was observed. It was observed an
ncrease in serum phosphate and bone resorption marker -
TX.
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